The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential

Build-A-Bear Workshop and Abbott Laboratories are highlighted as attractive dividend plays, both trading near lows with yields close to 3%. BBW is supported by a debt-free balance sheet, aggressive buybacks, international expansion, and a projected 9.3% earnings CAGR, with more than 70% upside to a $62 target. ABT trades at a forward P/E of 15.31x and is seen as undervalued despite segment weakness and lowered guidance, aided by strong liquidity, buybacks, and insider buying.

Analysis

This is a classic “low-expectations + capital return” setup, but the two names sit in very different places on the durability spectrum. BBW is the cleaner momentum-to-fundamental inflection: a debt-free balance sheet and buybacks give management real optionality, and international rollout can produce a second leg of margin expansion if store economics translate. The market is still treating it like a niche cyclical retailer, so any evidence of sustained comp lift or even modest unit productivity in new geographies could force rapid multiple re-rating over the next 2-3 quarters.

ABT is more of a quality-defense trade than a true catalyst story. The interesting second-order effect is that the combination of insider buying, repurchases, and a compressed multiple can stabilize sentiment before operating data does; that matters because large-cap healthcare often rerates on capital allocation credibility before top-line inflects. The flip side is that lowered guidance can keep the stock in a dead-money range for months if segment weakness persists, so the stock is more vulnerable to another cut than the article implies.

The consensus is probably underestimating how much of BBW’s upside is self-funded: every incremental dollar not spent on leverage reduction can be redirected into buybacks, which can materially amplify EPS growth in a flat-demand environment. For ABT, the market may be over-focusing on near-term softness and underpricing the embedded downside protection from liquidity and shareholder returns, but the setup still depends on management proving the guidance reset was conservative rather than the start of a longer demand slowdown. In both cases, the key watch item is whether capital returns are offsetting operating disappointment, or merely masking it.

Key Decisions for Investors

• Long BBW on a 3-6 month horizon; use a tight risk budget because the thesis is valuation re-rating plus buyback support, not macro beta. Best entry is on post-earnings weakness or market-wide retail selloffs; target a 20-30% move with downside limited to a failed comp/expansion update.
• Buy ABT on dips as a defensive dividend compounding name over 6-12 months; preferred entry is after any further guidance-related selloff. Risk/reward is modest but attractive for low-volatility capital preservation, with 10-15% upside if the market stops discounting the name for incremental weakness.
• Pair trade: long BBW / short a higher-multiple discretionary retailer basket for 1-2 quarters. The trade benefits if the market continues to reward self-help stories and penalize leverage-dependent peers; stop if BBW growth decelerates or the group rerates sharply higher on macro relief.
• For ABT, consider selling downside puts or a cash-secured put spread 1-2 quarters out to monetize elevated uncertainty while expressing a constructive view. This works best if the stock remains range-bound and capital returns provide a floor.
• If BBW rallies quickly into target-style upside, trim aggressively after a 25% gain; the multiple can re-rate fast, but the market may still be pricing in execution risk on international expansion.